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Bronchial asthma is a common problem with enormous medical and economics impacts. It is an inﬂammatory disease of the
airways associated with intermittent episodes of bronchospasm. Asthma is not uncommon in the elderly patients. Prevalence of
asthma is similar in older and younger adults. Asthma in the elderly patient is underdiagnosed because of false perceptions by both
patient and physician. The high incidence of comorbid conditions in the elderly patient makes the diagnosis and management
more diﬃcult. Correct diagnosis is demonstrated with spirometry. The goals of asthma treatment are to achieve and maintain
control of symptoms and to prevent development of irreversible airﬂow limitation. Asthma drugs are preferably inhaled because
this route minimizes systemic absorption and, thus, improves the ratio of the therapeutic beneﬁt to the potential side-eﬀects in
elderly patients.
Copyright © 2009 Domenico Lorenzo Urso. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. Epidemiology
Asthma is an inﬂammatory disorder of the airway associated
with airﬂow obstruction and bronchial hyperresponsiveness
that varies in severity across the spectrum of the disease.
The overall prevalence of asthma in adults and children
varies between countries, with estimates of 7% in France and
Germany, 11% in the USA, and 15%–18% in the United
Kingdom [1]. Although asthma has been considered, for
many years, a disease for childhood or young adulthood,
its prevalence is similar in older and younger people [2].
An incidence study demonstrated rate of newly diagnosed
asthma of 0.1% a year in those over 65 years of age
[3]. Elderly asthmatic patients mainly include subjects who
acquired the disease during childhood or adolescence and
whose disease progressed over time or relapsed after periods
ofremission(Elderlyasthmatic,long duration);however,the
ﬁrst manifestations of asthma may also occur in the late
adulthood or after 65 years of age (elderly asthmatic, late
onset) [4].
Little is known about the natural history of asthma
in elderly patients, but there is evidence in literature that
the elderly asthmatic patient is underdiagnosed [5, 6],
undertreated [5, 6], has un higher risk of hospitalization, has
a lower quality of life, and experiences greater morbidity and
mortality [7]. Underdiagnosed and undertreated of asthma
in the elderly may be due to diagnosis misclassiﬁcation or
under-reporting of symptoms [8]. Underestimation of the
prevalence of asthma may be due to confusion with chronic
obstructive pulmonary disease (COPD) [5].
The underdiagnosis may occur because of an age-
related reduction in perception of shortness of breath [9].
In elderly patients there is a close relationship between
the severity of wheezing complaints and impairment of
the forced expiratory volume in 1 second (FEV1). Elderly
patients with long-standing asthma have more severe airway
obstruction than patients with recently acquired disease
[4] but patients with newly diagnosed asthma experienced
a more rapid rate of decline FEV1 than patients with
chronic asthma [10]. Elderly patients did not show the
elevated rate of allergy skin tests reactivity or high serum
IgE levels [11]. However, elderly asthmatic patients have
more evidence of atophy than age-matched controls without
asthma as determined by increased immunoglobulin E (IgE)
levels and positive skin test [12]. Inhaled corticosteroids
(ICSs) have been show to slow this decline [13–15]. One
can speculate, then, that if aggressive anti-inﬂammatory
therapy had been started earlier in the course of the
disease, some of this damage to the airways may have been
prevented.2 Current Gerontology and Geriatrics Research
2. Deﬁnition andAssessment
Asthma is a chronic inﬂammatory disorder of the airways
in which many cells and cellular elements play a role. The
chronic inﬂammation is associated with airway hyperre-
sponsiveness that leads to recurrent episodes of wheezing,
breathlessness, chest tightness, and coughing, particularly at
night or in the early morning. These episodes are usually
associated with widespread, but variable, airﬂow obstruction
within the lung that is often reversible spontaneously or with
treatment [13]. Asthma is suggested by characteristic history
ofrecurrentepisodesofwheezing,breathlessness,chesttight-
ness, and/or cough especially at night or in early morning.
The certainty that asthma is correct diagnosis is increased
when either clinic spirometry or pulmonary function tests
demonstrate airﬂow obstruction that improves signiﬁcantly,
deﬁned as both a 12% and 200mL improvement in either
FEV1 in response to inhaled bronchodilator [16]. However
somestudiesindicatethatanincrease ≥10%ofthepredicted
FEV1 after inhalation of a short-acting bronchodilator may
be less subject to bias than measuring percent change from
baseline and may have a higher likelihood of separating
patients who have asthma from those who have COPD
[17, 18]. Spirometry before and after using a bronchodilator
should be an essential investigation although it may be
diﬃcult to perform in the elderly. In spite of all that in
the SARA study Bellia et al. are obtained, in terms of
acceptabilityandreproducibilityofFEV1inthevastmajority
of patients (aged 73 ± 6, 4 years) [19]. Measurement of
airways responsiveness to methacholine in specialized pul-
monary function laboratories may help to diagnose asthma
[20].
Conventional assessment of asthma severity has com-
bined assessment of symptoms, amounts of β-2 agonist used
to treat symptoms, and lung function (Table 1). Asthma is
classiﬁed as follows: Step 1: intermittent, with symptoms
occurring less than once a week and patients remaining
asymptomatic with normal peak expiratory ﬂow (PEF)
between attacks; Step 2: mild persistent, with symptoms
occurring more than once a week, but with < 1 attack·day
−1;
Step 3: moderate persistent, with daily attacks aﬀecting
activity, and Step 4: severe persistent, with continuous
limited physical activity [13]. Before treating elderly patients
with asthma, some other factors should be considered.
Elderly patients with suspect asthma require a rigorous and
systematic approach to their diagnosis and treatment. The
ﬁrst step in the care of these patients is evaluation and
testing directed at determining that asthma is the correct
diagnosis. There are a number of reasons why asthma is
underdiagnosed in elderly people (Table 2)[ 21]. It is critical
to make a diagnosis of asthma and to exclude other airway
diseases (Table 3). Comorbid conditions together with a less
typical clinical pattern have been shown to signiﬁcantly
aﬀect misdiagnosis. Indeed, patients with an erroneous
diagnosis of COPD have shown a lower Barthel index.
[19].
COPD is usually easy to distinguish from asthma but
sometimes the distinction from late asthma in older patients,
particularly in cigarette smokers, is diﬃcult and may be
Table 1: Classiﬁcation of asthma severity by clinical features [13].
Intermittent
Symptoms less than once a week
Brief exacerbations
Nocturnal symptoms not more than twice a month
FEV1 or PEF > 80% predicted
PEF or FEV1 variability < 20%
Mild Persistent
Symptoms more than once a week but less than once a day
Exacerbations may aﬀect activity and sleep
Nocturnal symptoms more than twice a month
FEV1 or PEF > 80% predicted
PEF or FEV1 variability < 20%–30%
Moderate Persistent
Symptoms daily
Exacerbations may aﬀect activity and sleep
Nocturnal symptoms more than once a week
FEV1 or PEF 60%–80% predicted
PEF or FEV1 variability > 30%
Severe Persistent
Symptoms daily
Frequent exacerbations
Frequent nocturnal asthma symptoms
FEV1 or PEF < 60% predicted
PEF or FEV1 variability > 30%
Table 2: Underdiagnosis of asthma [21].
Dyspnea is caused by aging
Reduction in perception of dyspnea
Self-limitation of activities
Social isolation
Depression
Misconception that adult-onset asthma is rare
Comorbid conditions
Table 3: Diseases that mimic asthma.
Chronic obstructive pulmonary Disease
Congestive heart failure
Bronchiectasis
Upper airway obstruction
Aspiration or inhaled foreign body
Hyperventilation/panic disorder
Churg-Strauss syndrome and other vasculitides
impossible. Both diseases are characterized by the presence
of airﬂow obstruction but have a distinct pathogenesis
and require unique treatment approaches. In general, the
degree of reversibility to a bronchodilator has been used
to determine whether a patient has COPD or asthma. The
ﬁxed airﬂow limitation of most patients can be deﬁned asCurrent Gerontology and Geriatrics Research 3
a post bronchodilator FEV1 of < 80% pred (in the presence
of a reduced FEV1/FVC) after a 7-to-14 day course of
oral corticosteroids (40mg per day for adults and 2mg/kg
per day in children). [23, 24] .An e g a t i v er e s p o n s em a y
indicate COPD, or rarely refractory asthma (corticosteroid-
resistant) [22, 25, 26]. The distinction between asthma and
COPD basic simply on spirometric parameters is diﬃcult;
therefore there is a need for more discriminatory tests such
as lung volume and the assessment of CO Diﬀusing capacity
(DLCO). Lung volumes (TLC, FRC, RV, RV/TLC%) are
elevated [27]. Moreover there is a signiﬁcant diﬀerence in
DLCO values between patients with COPD and asthma
[28]. The decreased DLCO may be directly related to the
loss of alveolar-capillary surface area that is associated with
emphysema [27].
Other risk factors that may contribute to a poor response
to conventional therapy must be excluding (Table 4)[ 22].
Some comorbid conditions may complicate asthma care. A
recent study showed that sinusitis, heartburn, COPD, Con-
gestive Heart Failure, and smoking are signiﬁcantly higher in
the over 65-year age group [29]. A number of medications
used for comorbid conditions may worsen asthma (Table 5)
[21]. ASA and NSAIDs are commonly prescribed in the
elderly and may cause late-onset asthma. On other hand
medication used for asthma worsens comorbid conditions
(Table 6)[ 21]. Oral and typical β-adrenergic blocking agents
[28] and other antiarrhythmic agents, including verapamil
[30], and others with acknowledged β-blocker potential can
exacerbate or cause asthma in those who are predisposed to
the disease [14, 31].
3. Treatment
The goals for successful management of asthma [13]a r et o
(1) achieve and maintain control of symptoms,
(2) prevent asthma exacerbations,
(3) maintain pulmonary function as close to normal
levels as possible,
(4) maintain normal activity levels, including exercise,
(5) avoid adverse eﬀects from asthma medications,
(6) prevent development of irreversible airﬂow limita-
tion,
(7) prevent asthma mortality.
Whenever possible, medications that might induce or aggra-
vate asthma should be withdrawn. In other respects, the
management of asthma in the elderly does not diﬀer from
that recommended for other age group, although particular
care should be taken in the selection of and instruction in
the use of inhaler devices. [14]. Asthma drugs are preferably
inhaled because this route minimizes systemic absorption
and, thus, improves the ratio of the therapeutic beneﬁt to the
potential side-eﬀects. Aerosolized medications that are used
to treat asthma are available as pressurized metered-dose
inhalers (MDIs), dry powder inhalers (DPIs), and nebulized
or “wet” aerosol. Asthma medications should be used at
Table 4: Risk factors [22].
Unidentiﬁed exacerbating factors
Unidentiﬁed allergens
Gastroesophageal reﬂux
Systemic diseases
Thyreotoxicosis
Carcinoid syndrome
Churg-Strauss syndrome and others vasculides
Drugs
β-blockers
Nonsteriodal anti-inﬂammatory drugs
Chronic infections
Mycoplasma
Chlamydia
Psycological factors
Table 5: Drugs that worsen asthma [21].
Hypertension β blockers and
ACE inhibitors
Glaucoma Topical β blockers
Arthritis
Acetylsalicylic acid
(ASA)/Non
steroidal
anti-inﬂammatory
drugs (NSAIDs)
Table 6: Asthma drugs that worsen comorbid conditions [21].
β agonist
Arrythmias
Tremors
Hypertension
Hypokalemia
Theophylline
Gastroesophageal reﬂux
Tremors
Insomnia
Corticosteroids Existing osteoporosis
the minimum dose and frequency required to maintain
acceptable asthma control.
Medications used to treat asthma are generally divided
into two main categories: relievers and controllers (Table 7).
Relievers are best represented by the inhaled short-acting
β2-agonist (SABA). Inhaled ipratropium bromide (IB) is
less eﬀective but is occasionally used as a reliver medication
in patient intolerant of SABA. Controllers include anti-
inﬂammatory medications, such as inhaled glucocorticos-
teroids (ICSs), leukotriene-receptor antagonists (LTRAs),
long-acting inhaled β2-agonist (LABA), sodium cromogly-
cate, and sustained release theophylline. [13–15]. Controller
medications used daily on a long-term basis to achieve and
maintain the goals of asthma treatment [13].
ICSs are the most eﬀective agents in this category. Several
studies are demonstrated that treatment with ICS for 1
monthormoresigniﬁcantlyreducesthepathologicalsignsof4 Current Gerontology and Geriatrics Research
Table 7: Recommended medications by level of severity [13].
Level of severity Daily controller medications Other treatment options
Intermittent asthma None necessary
Mild persistent asthma Low-dose ICS
Sustained-release
theophylline LTRAs
Sodium cromoglycate
Moderate persistent asthma Low-to-medium dose ICS plus
LABA
Sustained-release
theophylline LTRAs
Sodium cromoglycate
Severe persistent asthma
High-dose ICS plus LABA plus one
or more of the following, if need
Sustained-release theophylline
LTRAs
Oral CS
airway inﬂammation in asthma and airway hyperresponsive-
ness continues to improve with prolonged treatment. Local
adverse eﬀects from ICS include oropharyngeal candidiasis,
disphonia, and occasional coughing from upper airways irri-
tation. The use of a spacer (holding chamber) improves drug
delivery from an MDI. Spacers also reduce ICS deposition in
the mouth and oropharynx.
LABAs, including formoterol and salmeterol, are bron-
chodilator medications with activity persist for at least 12
hours. They should be considered when standard intro-
ductory doses of CSI fail to achieve control of asthma
before raising the dose of ICS. The principal side eﬀects
are dose dependent and are mediated via receptors on
vascular smooth muscle (tachycardia and tachyarrhythmia),
skeletal muscle (tremor, hypokalemia due to potassium
entry into muscle cells), and cells involved in lipid and
carbohydrate metabolism (increase in blood free fatty acid,
insulin, glucose, and pyruvate) [32].
LTRAsarearelativelynewclassofdrugsforthetreatment
of asthma. There is a substantial body of evidence for their
beneﬁt in the management of chronic asthma in both adults
and children, and particularly in speciﬁc types of asthma
such as exercise-induced and aspirin-sensitive asthma.
4. Conclusion
Asthma is an important healthcare problem worldwide.
Although the prevalence of asthma in older people is similar
to younger people, this disease is underdiagnosed and
undertreated. Asthma in the elderly patient adversely aﬀects
quality of life and results in a higher hospitalization rate and
mortality. Despite international guidelines recommending
appropriate therapy for asthma, they are, in elderly patient,
often poorly managed The high incidence of comorbid
conditions makes the diagnosis and management more
diﬃcult. Despite the availability of eﬀective antiasthma
drugs, many old patients with asthma remain uncontrolled.
Failure to achieve adequate control of asthma reveals a gap
between what is known to be eﬀective in asthma care and
what might be achieved if optimal medication combined
with management strategies could be implemented.
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